Axon Enterprise Files 8-K/A Amendment
Ticker: AXON · Form: 8-K/A · Filed: Dec 17, 2025 · CIK: 1069183
Sentiment: neutral
Topics: amendment, equity-securities
Related Tickers: AXON
TL;DR
Axon Enterprise filed an amendment to its 8-K, updating info on unregistered equity sales.
AI Summary
Axon Enterprise, Inc. filed an 8-K/A on December 17, 2025, to amend a previous filing concerning unregistered sales of equity securities. The amendment relates to events that occurred on December 9, 2025. No specific dollar amounts or details of the equity sales were provided in this amendment.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to information previously disclosed regarding unregistered equity sales by Axon Enterprise.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing and does not introduce new material events or financial disclosures.
Key Players & Entities
- Axon Enterprise, Inc. (company) — Registrant
- December 9, 2025 (date) — Earliest event date
- December 17, 2025 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report filed by Axon Enterprise, Inc., specifically concerning unregistered sales of equity securities and other events.
What is the date of the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 9, 2025.
When was this 8-K/A filing submitted to the SEC?
This 8-K/A filing was submitted to the SEC on December 17, 2025.
What was Axon Enterprise, Inc.'s former company name?
Axon Enterprise, Inc.'s former company name was TASER INTERNATIONAL INC, with a date of name change on February 12, 2001.
What is Axon Enterprise, Inc.'s principal executive office address?
Axon Enterprise, Inc.'s principal executive office is located at 17800 N. 85th St., Scottsdale, Arizona 85255.
Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-12-17 16:11:04
Key Financial Figures
- $0.00001 — ange on which registered Common Stock, $0.00001 Par Value AXON The NASDAQ Stock Market
- $19,000,000 — (the "Notes"), including an additional $19,000,000 aggregate principal amount of Notes exc
- $196,854,000 — xchange Transactions, Holders exchanged $196,854,000 in aggregate principal amount of the No
- $196,859,243.77 — or exchange consideration consisting of $196,859,243.77 in cash (inclusive of accrued interest
Filing Documents
- axon-20251209.htm (8-K/A) — 25KB
- 0001628280-25-057640.txt ( ) — 142KB
- axon-20251209.xsd (EX-101.SCH) — 2KB
- axon-20251209_lab.xml (EX-101.LAB) — 22KB
- axon-20251209_pre.xml (EX-101.PRE) — 13KB
- axon-20251209_htm.xml (XML) — 3KB
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities The information set forth under Item 8.01 below with respect to the shares of common stock to be issued pursuant to the Exchange Transactions (as defined herein) is incorporated into this Item 3.02 by reference, insofar as it relates to the unregistered sales of equity securities.
01 Other Events
Item 8.01 Other Events On December 16, 2025, the Company closed the separate, privately negotiated exchange transactions referenced in the Original 8-K (collectively, the "Exchange Transactions") with certain holders (the "Holders") of its 0.50% Convertible Senior Notes due 2027 (the "Notes"), including an additional $19,000,000 aggregate principal amount of Notes exchanged pursuant to a separate, privately negotiated exchange agreement entered into with a Holder on December 15, 2025, subsequent to the Original 8-K. In the Exchange Transactions, Holders exchanged $196,854,000 in aggregate principal amount of the Notes for exchange consideration consisting of $196,859,243.77 in cash (inclusive of accrued interest and cash in lieu of fractional shares) and an aggregate of 526,802 shares of the Company's common stock.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description 104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 17, 2025 Axon Enterprise, Inc. By: /s/ BRITTANY BAGLEY Brittany Bagley Chief Operating Officer and Chief Financial Officer